source
- Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategyIncyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
- City Therapeutics raises $99.5 million to advance three RNAi drug candidatesCity Therapeutics, a next‑generation RNA interference startup founded by former Alnylam executives, announced it has secured $99.5 million in financing. The capital will be used to move its first…